Viracta Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€633.20K - Cost of goods sold
€282.28K - Gross profit
€350.92K - SG&A expenses
€11.91M - R&D expenses
€28.39M - EBITDA
-€34.03M - D&A
€376.66K - EBIT
-€40.51M - Interest expenses
€2.73M - EBT
-€37.14M - Tax expenses
-€409.50K - Net income
-€37.14M
Cash flow statement
- Net deferred tax
-€1.67M - Non-cash items
€3.62M - Changes in working capital
€1.98M - Operating cash flow
-€29.85M - Capex
€0.00 - Other investing cash flow
€12.18M - Net investing cash flow
€37.17M - Total cash dividends paid
€0.00 - Issuance of common stock
€216.22K - Debt repayment
-€7.38M - Other financing cash flow
€77.22K - Net financing cash flow
-€7.09M - Foreign exchange effects
€0.00 - Net change in cash
€232.52K - Cash at end of period
€11.26M - Free cash flow
-€29.85M
Balance sheet
- Cash and cash equivalents
€11.26M - Cash and short-term investments
€18.13M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€575.72K - Total current assets
€18.71M - Property, plant & equipment
€95.24K - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€37.75K - Total non-current assets
€132.99K - Total assets
€18.84M - Accounts payable
€1.56M - Short-term debt
€14.51M - Other current liabilities
€8.45M - Total current liabilities
€24.52M - Long-term debt
€0.00 - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€0.00 - Total liabilities
€24.52M - Common stock
€3.43K - Retained earnings
-€253.50M - Other equity
€7.72K - Total equity
-€5.68M - Total liabilities and shareholders' equity
€18.84M
Company information
- Market capitalization
€603.42K - Employees
26 - Enterprise Value
€4.54M
Company ratios
- Gross margin
-
55.4% Much better than peer group: -196,101.1% - EBITDA margin
-
-5,374.9% Much better than peer group: -44,948,631.1% - EBIT margin
-
-6,397.0% Much better than peer group: -44,530,863.8% - EBT margin
-
-5,865.7% Much better than peer group: -45,130,358.7% - Net margin
-
-5,865.7% Much better than peer group: -45,265,915.1% - ROE
-
654.2% Much better than peer group: -136.6% - ROA
-
-197.1% Much worse than peer group: -52.5% - Asset turnover
-
3.4% Even with peer group: 5.8% - FCF margin
-
-4,714.9% Much better than peer group: -38,597,973.7% - FCF yield
-4,947.6% - Efficiency ratio
5,474.9% - Net sales per employee
-
€24.35K - Net income per employee
-
-€1.43M